Cited 62 times in
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2019-02-14T01:50:59Z | - |
dc.date.available | 2019-02-14T01:50:59Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/167251 | - |
dc.description.abstract | BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. METHODS: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. RESULTS: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95% CI 0.32-0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47-0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI 0.45-0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42-1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07-0.65), ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21-1.52). CONCLUSIONS: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group on behalf of Cancer Research UK | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Thomas Powles | - |
dc.contributor.googleauthor | Robert J. Motzer | - |
dc.contributor.googleauthor | Bernard Escudier | - |
dc.contributor.googleauthor | Sumanta Pal | - |
dc.contributor.googleauthor | Christian Kollmannsberger | - |
dc.contributor.googleauthor | Joanna Pikiel | - |
dc.contributor.googleauthor | Howard Gurney | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Se Hoon Park | - |
dc.contributor.googleauthor | Poul F. Geertsen | - |
dc.contributor.googleauthor | Marine Gross-Goupil | - |
dc.contributor.googleauthor | Enrique Grande | - |
dc.contributor.googleauthor | Cristina Suarez | - |
dc.contributor.googleauthor | David W. Markby | - |
dc.contributor.googleauthor | Alan Arroyo | - |
dc.contributor.googleauthor | Mark Dean | - |
dc.contributor.googleauthor | Toni K. Choueiri | - |
dc.contributor.googleauthor | Daniel George | - |
dc.identifier.doi | 10.1038/s41416-018-0164-0 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00406 | - |
dc.identifier.eissn | 1532-1827 | - |
dc.identifier.pmid | 30197417 | - |
dc.identifier.url | https://www.nature.com/articles/s41416-018-0164-0 | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.citation.volume | 119 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 663 | - |
dc.citation.endPage | 669 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, Vol.119(6) : 663-669, 2018 | - |
dc.identifier.rimsid | 61456 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.